BST2

Bone marrow stromal antigen 2 · Q10589 · BST2 on Sugi Atlas →

0 patent compounds predicted against BST2, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to BST2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Comparative Study of Strategies for Management of Duchenne Myopathy (DM) PHASE4UNKNOWN
Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation PHASE3UNKNOWN
Ixazomib for Desensitization PHASE2COMPLETED
Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients PHASE1/PHASE2COMPLETED
Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia. PHASE1/PHASE2UNKNOWN
Chemo Sensitization Before Hematopoietic Stem Cell Transplantation in Patients With Acute Leukemia in Complete Remission PHASE2UNKNOWN
AMD3100 Plus Mitoxantrone, Etoposide and Cytarabine in Acute Myeloid Leukemia PHASE1/PHASE2COMPLETED
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers PHASE2COMPLETED
CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies PHASE1/PHASE2UNKNOWN
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma PHASE1COMPLETED
Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma PHASE1COMPLETED
Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome PHASE1COMPLETED
Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease PHASE1COMPLETED
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I PHASE1WITHDRAWN
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) PHASE1COMPLETED
Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) in Combination With Azacitidine for the Treatment of Myelodysplastic Syndrome (MDS) PHASE1COMPLETED
A Clinical Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Injection (CNCT19) in the Treatment of Cluster of Differentiation 19 (CD19) Positive Relapsed or Refractory B Cell Malignancies EARLY_PHASE1UNKNOWN
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies EARLY_PHASE1UNKNOWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia nanUNKNOWN
Serum, Cellular and Imaging Markers of Arthritis in Psoriasis Patients nanCOMPLETED
The Expression of Antigens in Bone Marrow Samples From Volunteering Donors. nanCOMPLETED
Longitudinal Assessment of Marrow and Blood in Patients With Glioblastoma nanSUSPENDED
Expression of CD19 Complex in Lymphoproliferative Disorders nanUNKNOWN
Genomic and Phenotypic Determinants of Resistance to Immunotherapies in Multiple Myeloma nanCOMPLETED
FoxO3a and PU.1 in Acute Lymphoblastic Leukemia nanUNKNOWN
Prospective Cohort for Adult Hemophagocytosis nanRECRUITING
Prognostic Value of CD318 in AML at Assiut University Hospital. nanUNKNOWN
Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma nanCOMPLETED
Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS nanNOT_YET_RECRUITING
Oxford Pre-cancerous Lymphoproliferative Disorders Study nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a BST2 binder may also engage these)

ProteinNameSimilarity
Q8R2Q8 0.999 Q8R2Q8 →
Q811A2 0.991 Q811A2 →
Q6WRU0 0.989 Q6WRU0 →
Q96ST8 0.985 Q96ST8 →
Q9CZX2 0.983 Q9CZX2 →
A6QNP9 0.982 A6QNP9 →
Q9DA16 0.981 Q9DA16 →
Q9D9J7 0.981 Q9D9J7 →
Q6AY06 0.980 Q6AY06 →
Q9WV78 0.980 Q9WV78 →
Q91VC4 0.980 Q91VC4 →
Q86SQ7 0.979 Q86SQ7 →
Q6AZY7 0.979 Q6AZY7 →
B9V5F5 0.979 B9V5F5 →
Q2TAC2 0.979 Q2TAC2 →
B1AJZ9 0.979 B1AJZ9 →
Q05585 0.978 Q05585 →
Q5RFW0 0.978 Q5RFW0 →
IKBKG NF-kappa-B essential modulator 0.978 landscape →
P41159 0.978 P41159 →
P30204 0.978 P30204 →
Q80UF4 0.978 Q80UF4 →
Q4R703 0.978 Q4R703 →
Q6ZU80 0.978 Q6ZU80 →
Q8BVC4 0.978 Q8BVC4 →
Q8K299 0.977 Q8K299 →
Q6TFL3 0.977 Q6TFL3 →
Q9DEX1 0.977 Q9DEX1 →
Q9BX97 0.977 Q9BX97 →
Q5U3Z6 0.977 Q5U3Z6 →